A 2026 rat study suggests that SNAC, the absorption enhancer used in oral semaglutide (Rybelsus), may alter gut microbiota and increase inflammatory markers. While intriguing, the findings are preliminary and based on animal data. Experts say the benefits of semaglutide remain well established, and human studies are needed.
Table of contents [Show]
A new study has sparked discussion in the diabetes and weight management community: research published in the Journal of Controlled Release (February 2026) suggests that the absorption enhancer salcaprozate sodium (SNAC)—a key inactive ingredient in oral semaglutide (Rybelsus)—may influence gut microbiota and trigger certain inflammatory changes. This is based on a preclinical (animal) experiment in healthy rats, not human data. Here’s a balanced look at what the findings mean, why they matter, and what they don’t prove.Â
Semaglutide, the active ingredient in injectable Ozempic and Wegovy as well as the oral tablet Rybelsus, is a GLP-1 receptor agonist that helps control blood sugar in type 2 diabetes and promotes significant weight loss. While injections bypass the digestive system, turning it into a convenient daily pill required overcoming a major hurdle: stomach acid and enzymes destroy most peptide drugs like semaglutide before they can be absorbed.
Enter SNAC (salcaprozate sodium), a permeation enhancer that temporarily boosts absorption in the stomach. In Rybelsus tablets, SNAC is included in a relatively high dose (around 300 mg per tablet) to achieve the drug’s low bioavailability (about 0.4–1%). This formulation has been a game-changer for patients who prefer pills over needles, but gastrointestinal side effects (nausea, vomiting, diarrhea) remain common reasons for discontinuation.
Until now, SNAC was generally considered safe based on regulatory approvals and clinical use. This 2026 study is one of the first to systematically examine its repeated, chronic effects on the gut microbiome and related markers in vivo.
Researchers from the University of South Australia (led by Amin Ariaee and colleagues) gave healthy Sprague Dawley rats daily oral doses for 21 days: semaglutide alone, SNAC alone, the combination (SEM + SNAC as in Rybelsus), or a control.
Key observations from the study included several microbiological and inflammatory changes.
Gut microbiota shifts were observed. Alpha diversity, which represents the overall variety of bacteria, stayed stable. However, beta diversity, representing the composition of bacterial communities, changed significantly with SNAC exposure. There was a sharp drop in fiber-fermenting bacteria from the Muribaculaceae family (−62%) and the Bacteroidaceae family (−77%).
Short-chain fatty acids were also affected. Fecal butyrate, a key SCFA produced by gut bacteria, dropped dramatically (−77% with SNAC alone and −75% with the combination). Butyrate is important for maintaining gut barrier integrity, reducing inflammation, and supplying energy to colon cells.
Inflammatory and physiological markers showed changes as well. Plasma TNF-α, a pro-inflammatory cytokine, increased by about 70% with SNAC exposure. Some increases in IL-6 were observed in the combination group. Brain-derived neurotrophic factor (BDNF), which is associated with neuroprotection and brain health, dropped sharply by about 85% in the combination group. Organ level observations included increased liver weight and decreased caecum mass in SNAC-treated rats.
Correlation analysis suggested that the loss of beneficial bacteria families was associated with lower short-chain fatty acid production and higher TNF-α levels. This implies a possible sequence where microbiome disruption leads to reduced protective metabolites and increased systemic inflammatory signals.
Importantly, many of these effects appeared to be driven more strongly by SNAC than by semaglutide itself, since SNAC monotherapy often showed similar or stronger changes than the combination treatment.
This study has several limitations that are important to consider.
The experiment lasted only three weeks and was conducted in healthy rats rather than disease models or long-term human-like exposure.
The findings are associative rather than causal. The authors themselves emphasize that mechanistic validation is still required and that the results do not prove direct harm.
Animal models also differ significantly from humans. Gut microbiome composition, drug dosing relative to body weight, and gastrointestinal physiology vary between species, making direct translation uncertain.
The study also did not demonstrate any direct link to clinical outcomes such as worsening gastrointestinal symptoms, increased disease risk, or cognitive problems, despite the observed BDNF changes.
Oral semaglutide has already been used safely by millions of patients since its approval, with the most common adverse effects remaining gastrointestinal and generally transient.
The authors emphasize the need for further investigation and propose the development of microbiota-safe absorption enhancers for future oral peptide formulations.
For patients currently taking Rybelsus, this study is not a reason to stop treatment without medical advice. The benefits of semaglutide for blood sugar control and weight loss are well established through large human clinical trials, and this rat study does not alter the current risk-benefit profile.
Patients experiencing persistent gastrointestinal symptoms or other concerns should discuss their options with their healthcare provider. Alternatives such as injectable GLP-1 receptor agonists, which do not require SNAC, may be considered depending on the clinical scenario.
For the broader pharmaceutical field, this research highlights the importance of examining so-called inactive ingredients in advanced drug formulations. As oral biologics and peptide drugs continue to expand, understanding how absorption enhancers interact with the gut microbiome may help guide the development of safer delivery systems.
The gut microbiome plays a crucial role in metabolism, immunity, and even neurological health. For that reason, any formulation component that potentially alters microbial balance deserves careful long-term study.
In summary, emerging preclinical evidence suggests that SNAC in oral semaglutide may disrupt gut bacterial composition and trigger inflammatory changes in rats. These findings are intriguing but preliminary. Science progresses by questioning assumptions, and this study adds an important piece to the evolving understanding of oral peptide drug delivery.
For now, continued research including human studies will be necessary to determine whether these findings have meaningful clinical implications.
India faces a rapidly growing burden of metabolic diseases including diabetes, hypertension, obesity, and high cholesterol. A recent study highlights alarming trends across the Asia-Pacific region, with India leading in disease burden. Experts call for urgent nationwide prevention strategies, better nutrition policies, and lifestyle interventions to curb the crisis.
A new report reveals a surprising gap in Kerala’s healthcare data system. Despite being known for strong health indicators, only 11.41% of registered deaths in the state were medically certified in 2023. This raises serious concerns about mortality data accuracy, disease tracking, and evidence-based public health planning.
ProtoRadNet, an explainable AI model developed at IISER Bhopal, can interpret MRI, CT and X ray scans like a radiologist. Built over 1.5 years and tested on public datasets with 92% accuracy and 190+ clinical reports, the system highlights suspicious regions and explains findings. This innovation could help address India’s radiologist shortage and improve diagnostic speed.
